Summary
A total of 37 selected patients with clinical stage T2b or T3 prostate cancer received androgen deprivation prior to radical retropubic prostatectomy. A luteinizing hormone-releasing hormone (LHRH) analog alone was given to 15 individuals; 19 received an LHRH analog with flutamide. Three underwent bilateral orchiectomy instead of chemical castration. The duration of androgen deprivation prior to radical prostatectomy varied from 3 to 16 months, with 31 individuals undergoing induction therapy for 3–6 months. Three received androgen deprivation for more than 1 year. In all, 15 patients had clinical stage T2b disease and 22, stage T3 prostate cancer. The prostate size decreased approximately 30%–50% following induction therapy. Prostate-specific antigen (PSA) values decreased in all 19 instances where this was obtained. In all, 6 of 15 (40%) patients with clinical T2b lesions and 9 of 22 (41%) with clinical T3 tumors had a positive surgical margin; 5 (13%) had 1 or more positive lymph nodes. Androgen deprivation was continued following surgery in 13 cases. Only one patient received postoperative radiation therapy. After a mean follow-up period of 33 months, 35 (95%) patients are alive. Two patients died, one of poorly differentiated prostate cancer with subsequent metastasis and one of a myocardial infarction 33 months after surgery without showing any evidence of disease. Of 23 patients without postoperative adjuvant therapy, 6 (26,1%) progressed (PSA level, >0.4 ng/ml). None of the patients who underwent adjuvant therapy progressed over a follow-up period of 6–75 months (mean, 38 months). Although the low incidence of positive lymph nodes and the apparent reduction in tumor size after androgen deprivation are encouraging, the benefits of this approach must await the completion of ongoing randomized trials.
Similar content being viewed by others
References
Scardino PT, Shinohara K, Wheeler TM, Carter SSC (1989) Staging of prostate cancer: value of ultrasonography. Urol Clin North Am 16:713–734
Scardino PT, Wheeler TM (1985) Prostatic biopsy after irradiation therapy for prostatic cancer. Urology 25 [Suppl]:39–46
Levine AC, Droller MA, Kirschenbaum A, Gabrilove JL, Kaplan P (1989) Serum prostate antigen levels in patients with benign prostatic hypertrophy treated with leuprolide. Urology 34:10–13
Murphy WM, Soloway MS, Barrows GH (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68:821–828
Matzkin H, Eber P, Todd B, Zwaag R van der, Soloway MS (1992) prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 70:2302–2308
Soloway MS (1984) Newer method of hormonal therapy for prostate cancer. Urology 24 [Suppl]:30–40
Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacourciere Y, Emond J, Monfette G (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7:67–74
Crawfond ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424
Walsh PC, Lepor H, Eggleston JC (1985) Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4:472–485
Catalona WJ, Bigg SW (1990) Nerve sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143:538–554
Paulson DF, Lin GH, Hinshaw W, Stephani S, Uro-Oncology Research Group (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128:502–504
Olsson CA, Babayan R, White RD (1985) Surgical management of stage B or C prostatic carcinoma: radical surgery vs radiotherapy. Urology 25 [Suppl]:30–35
Kennedy TJ, Sonneland AM, Marlett MM, Troup RH (1992) Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147:891–893
McCullough DL, Prout GR Jr, Daly JJ (1974) Carcinoma of the prostate and lymphatic metastases. J Urol 111:65–71
Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135:1199–1205
Jones EC (1990) Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144:89–93
Colston JAC, Brendler H (1947) Endocrine therapy in carcinoma of the prostate: preparation of patients for radical perineal prostatectomy. JAMA 134:848–853
Scott WW, Boyd HL (1969) Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol 101:86–92
Soloway MS (1991) Medical/surgical treatment for advanced prostate cancer. Abstract 58–59, 4th International Symposium of the Foundation for Promotion of cancer Research
Paulson DF, Stone AR, Walther PJ, Tucker JA, Cox EB (1986) Radical prostatectomy: anatomical predictors of success or failure. J Urol 136:1041–1043
Donohue RE, Fauver HE, Whitesel JA, Augspurger RR, Pfister RR (1981) Prostatic carcinoma. Influence of tumor grade on results of pelvic lymphadenectomy. J Urol 17:435–440
Flamm J, Fischer M, Höltl W, Pflüger H, Tomschi W (1991) Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur Urol 19:192–195
de Kernion JB, Neuwirth H, Stein A, Dorey F, Stenzi A, Hannah J, Blyth B (1990) Prognosis of patients with stage D1 carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 144:700–703
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soloway, M.S., Hachiya, T., Ruiz, H.E. et al. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen. World J Urol 11, 221–226 (1993). https://doi.org/10.1007/BF00185074
Issue Date:
DOI: https://doi.org/10.1007/BF00185074